Depression Specialty Clinic
Program Director

RothschildAnthony J. Rothschild, M.D.
Professor and Irving S. and Betty Brudnick Endowed Chair of Psychiatry, University of Massachusetts Medical School
Director, UMass Medical Depression Center
Program Director, Mood Disorders Comprehensive Consultation Clinic at UMassMemorial Medical Center
Director, Center for Psychopharmacologic Research and Treatment

Anthony J. Rothschild, M.D. is the Irving S. and Betty Brudnick Endowed Chair and Professor of Psychiatry at the University of Massachusetts Medical School and its clinical partner, UMass Memorial Medical Center, Worcester, Massachusetts. Dr. Rothschild has spent more than 25 years in both clinical and research settings diagnosing and treating patients with psychotic depression and studying the diagnostic challenges, biology, course, and treatment of this serious disorder. Dr. Rothschild has published his work in numerous scientific journals including the American Journal of Psychiatry, Archives of General Psychiatry, Biological Psychiatry, Journal of Clinical Psychiatry, Journal of Clinical Psychopharmacology, and others. He is co-editor with Owen Wolkowitz, M.D. of Psychoneuroendocrinology: The Scientific Basis of Clinical Practice, American Psychiatric Press, 2003, as well as the author of the Clinical Manual for Diagnosis and Treatment of Psychotic Depression, American Psychiatric Press, November 2009 (APPI video), The Evidenced-Based Guide to Antipsychotic Medications, American Psychiatric Press, January 2010, and his latest book the The Evidenced-Based Guide to Antidepressant Medications, American Psychiatric Press, January 2012. A Distinguished Fellow of the American Psychiatric Association, a Fellow of the American Psychopathological Association and the Collegium Internationale Neuro-Psychopharmacologicum and a member of the American College of Neuropsychopharmacology, the American Society of Clinical Psychopharmacology, and the International Society of Psychoneuroendocrinology among other professional associations, Dr. Rothschild has received many research grants and has presented at numerous local, national and international meetings. He is on the Editorial Board of the Journal of Clinical Psychiatry, Depression and Anxiety, and Current Psychiatry and serves as a journal referee for the American Journal of Psychiatry, Journal of Clinical Psychiatry, Journal of Clinical Psychopharmacology, the New England Journal of Medicine, the Harvard Review of Psychiatry, and others. Dr. Rothschild has received many awards and honors including the Massachusetts Psychiatric Society Outstanding Psychiatrist Award for Research, numerous teaching and mentoring awards, and has been consistently named to the Best Doctors of America and Boston Magazine, Best Doctors. Dr. Rothschild received his bachelor s degree from Princeton University, his medical degree from the University of Pennsylvania School of Medicine, and did his psychiatry residency at McLean Hospital/Harvard Medical School.

Representative Publications:
  1. Rothschild AJ (ed): Evidence Based Guide to Antidepressant Medications. Washington: American Psychiatric Press, 2012.
  2. Dunlop BW, Li T, Kornstein SG, Friedman ES, Rothschild AJ, Pedersen R, Ninan P, Keller M, Trivedi MH. Concordance between clinician and patient ratings as predictors of response, remission, and recurrence in major depressive disorder. J Psychiatry Research, 2011; 45:96-103.
  3. Blumberger DM, Mulsant BH, Emeremni C, Houck P, Andreescu C, Mazumdar S, Whyte E, Rothschild AJ, Flint AJ, Meyers BS. Impact of prior pharmacotherapy on remission of psychotic depression in a randomized controlled trial. J Psychiatry Research 2011; 45:896-901.
  4. Byatt N, Rothschild AJ, Riskind P, Ionete C, Hunt A: Relationships between multiple sclerosis and depression. J Neuropsychiatry Clin Neurosci 23:198-200, 2011.
  5. Flint AJ, Peasley-Miklus C, Papademetriou E, Meyers BS, Mulsant BH, Rothschild AJ, Whyte EM. STOP-PD Study Group. Effect of age on the frequency of anxiety disorders in major depression with psychotic features. Am J Geriatric Psychiatry 2010; 18:404-412.
  6. Trivedi MH, Dunner DL, Kornstein SG, Thase ME, Zajecka JM, Rothschild AJ, Friedman ES, Shelton RC, Keller MB, Kocsis JH, Gelenberg A. Psychosocial Outcomes in Patients with Recurrent Major Depressive Disorder During 2 Years of Maintenance Treatment With Venlafaxine Extended Release. J Affective Disorders, 2010; 126:420-429.
  7. Dunlop BW, Li T, Kornstein SG, Friedman ES, Rothschild AJ, Pedersen R, Ninan P, Keller M. Correlation between patient and clinician assessments of depression severity in the PREVENT study. Psychiatry Research 2010; 177:177-183.
  8. Rothschild AJ (ed): Evidence Based Guide to Antipsychotic Medications. Washington: American Psychiatric Press, 2010.
  9. Rothschild AJ (ed): Clinical Manual for the Diagnosis and Treatment of Psychotic Depression. Washington: American Psychiatric Press, 2009.
  10. Glezer A, Byatt N, Cook Jr. R, Rothschild AJ. Polypharmacy Prevalence Rates in the Treatment of Unipolar Depression in an Outpatient Clinic, J Affective Disorders, 2009; 117:18-23.
  11. Meyers BS, Flint AJ, Rothschild AJ, Mulsant BH, Whyte EM, Peasley-Miklus C, Papademetriou E, Leon AC, Heo M for the STOP-PD Study Group. A Double-Blind Randomized Controlled Trial Of Olanzapine Plus Sertraline Versus Olanzapine Plus Placebo For Psychotic Depression -- The Stop-PD Study, Arch Gen Psychiatry, 2009; 66:838-847.
  12. Rothschild AJ, Dunlop BW, Dunner DL, Friedman ES, Gelenberg A, Holland P, Koscis JH, Kornstein SG, Shelton R, Trivedi MH, Zajecka JM, Goldstein C, Thase ME, Pedersen R, Keller MB. Assessing Rates and Predictors of Tachyphylaxis During the Prevention of Recurrent Episodes of Depression With Venlafaxine ER for Two Years (PREVENT) Study. Psychopharmacology Bulletin, 2009; 42:5-20.
  13. Smith E, Rothschild AJ, Heo M, Peasley-Miklus C; Caswell M; Papademetriou, E, Flint AJ, Mulsant BH, Meyers BS, Study of the Pharmacotherapy of Psychotic Depression (STOP-PD) Collaborative Study Group. Weight gain during olanzapine treatment for psychotic depression: effects of dose and age. Int J of Psychopharmacology, 2008; 23:130-137.
  14. Rothschild AJ, Winer J, Fratoni S, Gabriele M, Kasapinovic S, McShea M, Flint A, Meyers B, Mulsant B, Study of the Pharmacotherapy of Psychotic Depression(STOP-PD). Missed Diagnosis of Psychotic Depression at 4 Academic Medical Centers. J Clin Psychiatry, 2008; 69:1293-1296.
  15. Rothschild AJ: The Rothschild Scale for Antidepressant Tachyphylaxis (RSAT): Reliability and Validity, Comprehensive Psychiatry, 2008; 49:508-513.
  16. Schaffer A, Flint AJ, Smith E, Rothschild AJ, Mulsant BH, Szanto K, Peasley-Miklus C, Heo M, Papademetriou E, Meyers BS, for the Study of the Pharmacotherapy of Psychotic Depression (STOP-PD) Study Group. Correlates of Suicidality Among Patients with Psychotic Depression: Results from the STOP-PD Trial. Suicide and Life Threatening Behavior, 2008; 38:403- 414.
  17. Kamara TS, Whyte EM, Mulsant BH, Peasley-Miklus C, Rothschild AJ, Flint AJ, Heo M, Papademetriou E, Mathis ER, Meyers BS; for the STOP-PD Group. Does major depressive disorder with somatic delusions constitute a distinct subtype of major depressive disorder with psychotic features? J Affective Disorders, 2008;112:250-255.
  18. Andreescu C, Mulsant BH, Peasley-Micklus C, Rothschild AJ, Flint AJ, Heo M, Caswell M, Whyte EM, Meyers BS for the STOP-PD Study Group: Persisting low use of antipsychotics in the treatment of major depressive disorder with psychotic features. J Clin Psychiatry, 2007; 68:194-200
  19. Kocsis J, Thase M, Trivedi M, Shelton R, Kornstein S, Nemeroff C, Friedman E, Gelenberg A, Dunner D, Hirschfeld R, Rothschild AJ, Ferguson J, Schatzberg A, Zajecka J, Pedersen R, Yan B, Ahmed S, Musgnung J, Ninan P, Keller M. Prevention of Recurrent Episodes of Depression With Venlafaxine ER in a One-Year Maintenance Phase From the PREVENT Study J Clin Psychiatry, 2007; 68:1014-1023.
  20. Keller M, Trivedi MH, Thase ME, Shelton R, Korstein S, Nemeroff CB, Friedman ES, Gelenberg A, Koscis JH, Dunner DL, Dunlop B, Hirschfeld R, Rothschild AJ, Ferguson J, Schatzberg A, Zajecka J, Pedersen R, Yan B, Ahmed S, Schmidt M, Ninan P. The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT)Study: Outcomes from Acute and Continuation Phases. Biol Psychiatry, 2007; 62:1371-1379.
  21. Keller MB, Trivedi MH, Thase ME, Shelton RC, Kornstein SG, Nemeroff CB, Friedman ES, Gelenberg AJ, Kocsis JH, Dunner DL, Hirschfeld RM, Rothschild AJ, Ferguson JM, Schatzberg AF, Zajecka JM, Pedersen RD, Yan B, Ahmed S, Musgnung J, Ninan PT. The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the 2-year and combined maintenance phases. J Clin Psychiatry, 2007; 68:1246-56.
  22. Rothschild AJ, Williamson DJ, Tohen MF, Schatzberg A, Andersen SW, Van Campen LE, Sanger TM, Tollefson GD: Olanzapine-Fluoxetine combination for Major Depression with Psychotic Features. Journal of Clinical Psychopharmacology, 2004; 24:365-373.
  23. Schatzberg AF, Rothschild AJ: Psychotic (delusional) major depression: Should it be included as a distinct syndrome in DSM-IV? Am J Psychiatry, 1992; 149:733-745.